Gomisin A ameliorates metastatic melanoma by inhibiting AMPK and ERK/JNK-mediated cell survival and metastatic phenotypes

Phytomedicine. 2020 Mar:68:153147. doi: 10.1016/j.phymed.2019.153147. Epub 2019 Dec 7.

Abstract

Background: Gomisin A (G.A), a lignan compound extracted from the fruits of Schisandra chinensis, is known to exert anti-tumor effects on hepatocarcinoma and colorectal cancer cells. Suppression of proliferation and metastatic abilities of cancer cells are some effective cancer treatment methods.

Purpose: The objective of this study is to investigate the effects of G.A on metastatic melanoma, and the mechanism by which it affects metastatic melanoma.

Study design: The anti-proliferative and anti-metastatic effects of G.A were observed in in vitro and in vivo.

Methods: WST assay and flow cytometry were conducted to investigate the effect of G.A on proliferation, cell cycle arrest, and apoptosis in metastatic melanoma cell lines. Migration and invasion abilities of G.A-treated melanoma cells were observed by wound healing and invasion assays.

Results: G.A (25-100 μM) decreased the viability of melanoma cells by inducing cell cycle arrest and apoptosis. These anti-proliferative effects of G.A were found to be mediated by AMPK, ERK, and JNK activation. G.A (5-20 μM) decreased the migration and invasion of melanoma cells by suppressing epithelial-mesenchymal transition (EMT). Consequently, G.A (2-50 mg/kg) inhibited lung metastasis by suppressing EMT and inducing cell cycle arrest and apoptosis in melanoma cells.

Conclusion: These results conclude that G.A has the potential to reduce metastatic melanoma through its anti-proliferative and anti-metastatic effects.

Keywords: Apoptosis; Cell cycle arrest; Epithelial-mesenchymal transition; Gomisin A; Melanoma; Metastasis.

MeSH terms

  • AMP-Activated Protein Kinases / antagonists & inhibitors
  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Apoptosis / drug effects
  • Cell Cycle Checkpoints / drug effects
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Cyclooctanes / pharmacology*
  • Dioxoles / pharmacology*
  • Epithelial-Mesenchymal Transition / drug effects
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Humans
  • Lignans / pharmacology*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • MAP Kinase Kinase 4 / metabolism
  • Melanoma / drug therapy*
  • Melanoma / metabolism
  • Melanoma / pathology*
  • Mice, Inbred C57BL
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents, Phytogenic
  • Cyclooctanes
  • Dioxoles
  • Lignans
  • schizandrol B
  • Extracellular Signal-Regulated MAP Kinases
  • AMP-Activated Protein Kinases
  • MAP Kinase Kinase 4